The Absolute Effect / Oncology Evidence / Evidence Index
TALAPRO-2
In metastatic castration-resistant prostate cancer, does talazoparib plus enzalutamide improve survival over enzalutamide alone, and how does benefit vary by HRR status?
Registry: NCT03395197 · Evidence reviewed 9 November 2026 · Aliases and follow-up publications consolidated.
Phase III double-blind placebo-controlled; all-comer cohort n=805.Primary-source evidence summaryStudy design, population and eligibility
Phase III double-blind placebo-controlled; all-comer cohort n=805.
mCRPC progressing on ADT; chemotherapy-naive in mCRPC setting.
Treatment and comparator
Intervention: Talazoparib + enzalutamide + ADT.
Comparator: Placebo + enzalutamide + ADT.
Endpoints
rPFS primary; OS key secondary.
Key efficacy and clinical outcomes
Final all-comer OS 45.8 vs 37.0 mo (HR 0.80); HRR-deficient cohort 45.1 vs 31.1 mo (HR 0.62).
Source-reported outcome visualization
Values are reproduced from the cited report; bars are scaled within this figure. First-line mCRPC · HRR-deficient and all-comer cohorts
Median survival and hazard ratios are not fixed-time event risks; NNT is not inferred from them.
Toxicity and treatment burden
Grade ≥3 anaemia 49% vs 4%, neutropenia 19% vs 1% in all-comer cohort.
Absolute effect and NNT/NNH
Benefit greatest in HRR-deficient/BRCA-altered disease; genomic testing and marrow reserve matter.
NNT/NNH is not calculated unless a directly reported, comparable fixed-time risk difference supports it. Median survival and hazard ratios alone do not provide an NNT.
Critical interpretation and limitations
Benefit greatest in HRR-deficient/BRCA-altered disease; genomic testing and marrow reserve matter.
This page is an evidence summary, not a substitute for multidisciplinary assessment or patient-specific decision-making.
Current-practice context
Review date: 9 November 2026. Primary publication and selected follow-up sources were reviewed. Full disease-specific guideline, regulatory-label and sequencing audit remains pending; verify current local recommendations and biomarker eligibility before clinical application.